Hideshima, Teru

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 2,632

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 932

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 861

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 804

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell

Multiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways

Cited by 694

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood

Multiple Myeloma Research and TreatmentsCell death mechanisms and regulation

Cited by 669

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Santo, L., Hideshima, T., Kung, A. L., Tseng, J.-C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J. H., Mazitschek, R., Ogier, W. C., et al. (2012) · Blood

Multiple Myeloma Research and TreatmentsHistone Deacetylase Inhibitors Research

Cited by 616

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell

Ubiquitin and proteasome pathwaysMultiple Myeloma Research and Treatments

Cited by 589

Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer

Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 569

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 523

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene

Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 478

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., et al. (2009) · Blood

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 363

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 309

Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control

Multiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways

Cited by 292

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 164

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 162

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia

Histone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments

Cited by 159

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

Hayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsTGF-β signaling in diseases

Cited by 110

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsVitamin C and Antioxidants Research

Cited by 109

RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 109

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

Gullà, A., Hideshima, T., Bianchi, G., Fulciniti, M., Kemal Samur, M., Qi, J., Tai, Y.-T., Harada, T., Morelli, E., Amodio, N., et al. (2018) · Leukemia

Cancer-related gene regulationMultiple Myeloma Research and Treatments

Cited by 102

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Ogiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 92

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications

Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017) · Leukemia

Histone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments

Cited by 89

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity

Liu, J., Song, T., Zhou, W., Xing, L., Wang, S., Ho, M., Peng, Z., Tai, Y.-T., Hideshima, T., Anderson, K. C., et al. (2019) · Leukemia

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 83